Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 17/20 | 0.82 |
| ▸ | RAF1 | P04049 | 1/20 | 0.73 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.66 |
| ▸ | KIT | P10721 | 2/20 | 0.55 |
| ▸ | KDR | P35968 | 2/20 | 0.55 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.55 |
| ▸ | LYN | P07948 | 1/20 | 0.55 |
| ▸ | LCK | P06239 | 1/20 | 0.55 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL380035 | 1.00 | MAPK13 (0.82) | MAPK13RAF1MAPK14KITKDR | |
| SCHEMBL380272 | 0.91 | MAPK13 (1.00) | MAPK13RAF1MAPK14KDRLCK | |
| SCHEMBL435673 | 0.88 | MAPK13 (1.00) | MAPK13RAF1MAPK14 | |
| SCHEMBL3622995 | 0.87 | MAPK13 (1.00) | MAPK13RAF1MAPK14 | |
| SCHEMBL380693 | 0.85 | MAPK13 (1.00) | MAPK13RAF1MAPK14 | |
| SCHEMBL379741 | 0.83 | MAPK13 (0.75) | MAPK13RAF1MAPK14 | |
| SCHEMBL3618303 | 0.83 | MAPK13 (0.85) | MAPK13RAF1MAPK14 | |
| SCHEMBL379524 | 0.83 | MAPK13 (0.76) | MAPK13RAF1MAPK14 | |
| SCHEMBL379661 | 0.82 | MAPK13 (0.76) | MAPK13RAF1MAPK14 | |
| SCHEMBL3616016 | 0.82 | MAPK13 (0.74) | MAPK13RAF1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2086973-B1 | IMIDAZO- AND TRIAZOLO-PYRIDINE COMPOUNDS AND METHODS OF USE THEROF | AMGEN INC (US) | 2012-01-25 | — | — | EP | claimed |
| US-7700593-B2 | Imidazo- and triazolo-pyridine compounds and methods of use thereof | AMGEN INC. (US) | 2010-04-20 | — | — | US | claimed |
| US-20080161303-A1 | Imidazo- and triazolo-pyridine compounds and methods of use thereof | AMGEN INC. (US) | 2008-07-03 | — | — | US | claimed |
| EP-2086973-B1 | IMIDAZO- AND TRIAZOLO-PYRIDINE COMPOUNDS AND METHODS OF USE THEROF | AMGEN INC (US) | 2012-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161303-A1 | Imidazo- and triazolo-pyridine compounds and methods of use thereof | MAPK1, MAP3K1, MAP3K7 | MAPK13 37/4885RAF1 42/4885MAPK14 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.